Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Pfs25 VLP-FhCMB Malaria Vaccine
NCT02013687Phase 1Completed
- Sponsor
- Fraunhofer-Gesellschaft
- Start
- Oct 2013
- Primary completion
- Aug 2014
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of Pfs25 VLP-FhCMB + Alhydrogel in malaria (4 arms), sponsored by Fraunhofer-Gesellschaft. Primary endpoints: Subjects With at Least One Adverse Event at 336 days, Subjects With Solicited Systemic Adverse Events at 336 days and 1 more. Started Oct 2013; status: completed.
02
Drugs
Pfs25 VLP-FhCMB + Alhydrogel
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02013687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02013687.